Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Corp. (Lexaria Bioscience Corp.) on March 16, 2011. The filing reports a specific corporate event regarding the exercise of stock options by a company director.
Key Financial Metrics
- Proceeds from Equity Exercise: US$21,250
- Shares Issued: 106,250 common shares
- Exercise Price: Approximately US$0.20 per share (calculated from gross proceeds and share count)
- Use of Proceeds: General working capital
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide a clear value for these metrics as this is a current report on a specific transaction, not a periodic financial statement.
Material Changes
On March 16, 2011, David DeMartini, a Director of the Company, exercised 106,250 stock options, converting them into 106,250 common shares. This transaction resulted in an immediate increase in the company's cash position and outstanding share count.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard regulatory context. The transaction was conducted pursuant to the exemption from registration provided under Rule 506 of Regulation D, with the subscriber representing status as an "accredited investor."
Investor Verification Checklist
- Verify the updated total number of outstanding shares following the issuance of 106,250 new shares.
- Confirm the impact of the US$21,250 cash inflow on the company's current liquidity position.
- Review the press release filed as Exhibit 99.1 for additional context on the option exercise.
- Check subsequent filings for any further unregistered sales of equity securities.